Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.

Disclosed are compositions and formulations of non-porcine lipase and methods of treatment and manufacture thereof.

A drug delivery device includes an enteric capsule enclosing an internal volume and a plurality of drug containing particles positioned within the internal volume. Each of the plurality of drug containing particles includes a matrix body and an active pharmaceutical ingredient (API) distributed within the matrix body. The plurality of drug containing particles are configured to penetrate tissue, such as intestinal mucosa.

The disclosure relates to methods and compositions to treat an eosinophilic disease or disorder. More particularly, the disclosure provides methods and compositions for treating eosinophilic esophagitis.

Disclosed is to a new pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production processes and uses, in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and/or the gastro-intestinal tract.

The invention provides a die suitable for producing a multi-chamber softgel capsule. The die comprises a die pocket defined by a die pocket wall and a bottom surface. The die comprises one or more partitioning walls dividing the die pocket into two or more chambers The top of the land of the partitioning walls have a lowest point that is lower than the plane formed by the top of the land along the perimeter of the die pocket wall by a gap. A die roll comprising a plurality of the dies is also provided, as well as rotary-die encapsulation machine comprising the die roll.

Disclosed herein is a chewable article for oral mucosa delivery of a composition. The chewable system comprises a chewable base with the composition embedded, coated, integrated or dispersed therein. The composition may be pressurized, oxygenated, and/or atomized. The composition may be released as an aerosol. In one embodiment, the chewable system comprises a pressurized capsule that dissolves or ruptures in the mouth to release a burst of the composition. The chewable system may be configured to allow the composition facing to the buccal mucosa.

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N.sup.7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.

A method for designing and manufacturing a long release capsule for extended delivery of a drug to a patient in an ingestible capsule. The method includes determining a drug volume to be delivered and a drug delivery rate. A buoyancy element is selected based on the drug volume. A release port is selected based on the drug delivery rate and the properties of the drug. The design elements are used to produce a capsule design for an ingestible capsule. The design of the capsule is used to generate manufacturing instructions and produce the capsule.

It is proposed that dissipation of relative benefit during long-term treatment is due to long-term tolerance to stimulant medications. To improve adherence and persistence of medication use, it is advantageous to develop medications that are not undermined by long-term tolerance. Disclosed herein in certain implementations are formulations and methods relating to an alternative formulation of medication for the treatment of ADHD based on two principles: (a) retaining the initial immediate-release component of controlled-release formulations that targets a neural mechanism, which elicits acute tolerance, and (b) replacing the subsequent sustained-release component with a medication that maintains the initial benefit by targeting a different neural mechanism does not elicit tolerance, thus allowing more time for acute tolerance elicited by the initial bolus dose of stimulant medication to dissipate completely each day and avoid carry-over and accumulation that results in long-term tolerance.